p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling
Abstract Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths primarily due to chemoresistance. Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Substantial evidence suggests the...
Main Authors: | Yize Zhang, Chae Young Han, Fu Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Robin J. Parks, Yi-Jun Tang, Mei-Fang Wang, Liang Liu, Benjamin K. Tsang, Elaine Lai-Han Leung |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12935-019-0910-2 |
Similar Items
-
TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway
by: Ying Xing, et al.
Published: (2018-07-01) -
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2021-08-01) -
Study of a Molecular Promoter for Enhancing Cisplatin Cancer Chemotherapy
by: Nguyen, Jenny
Published: (2010) -
Study of a Molecular Promoter for Enhancing Cisplatin Cancer Chemotherapy
by: Nguyen, Jenny
Published: (2010) -
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
by: Xibin Zhuang, et al.
Published: (2019-06-01)